Pfizer looks to electronics to streamline trials

Pfizer ($PFE) is trying out a new "all-electronic" approach in a clinical study involving the approved overactive bladder pill Detrol, with an eye toward finding ways to streamline its trials for experimental drugs, the Wall Street Journal reports. Nobody spends more on R&D than Pfizer, giving the drug giant reason to look for ways of doing clinical research more efficiently. The company's ($PFE) Detrol study will rely heavily on the use of smartphones and computers to allow patients to report their progress, patient recruitment will be done online, and one group from the University of California, San Francisco, will manage the trial. How's that for efficient? Report

Suggested Articles

Less than two years after taking the reins from founding chief Rusty Williams, Five Prime Therapeutics’ CEO Aron Knickerbocker is exiting the company.

A Roche compound that was designed to treat rheumatoid arthritis could improve the heart's ability to repair itself, a Vanderbilt team found.

After a whirlwind year and two quick-fire raises, cancer startup Black Diamond Therapeutics has nabbed Yumanity, Merck KGaA and SR One veterans to help head up…